NasdaqGS:DFTXPharmaceuticals
Assessing Definium Therapeutics (DFTX) Valuation After Wider Q1 2026 Losses And Strong Recent Share Returns
Definium Therapeutics (DFTX) stock is in focus after the company reported first quarter 2026 results, including a net loss of US$77.1 million, compared with US$23.35 million in the same period a year earlier.
See our latest analysis for Definium Therapeutics.
The earnings update comes after a strong run in the stock, with a 90 day share price return of 37.28% and a year to date share price return of 70.09%. Meanwhile, the 1 year total shareholder return of 259.13% and 3 year total shareholder...